Avalyn Pharma Inc. Common Stock
AVLN | NASDAQ
$25.29
-$0.34 (-1.33%)
Nov 2, 2026, 11:25 AM ET · Market open
TTM Period Ending | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 |
|---|---|---|
Cash & Equivalents | 264.2M | 92.31M |
Short-Term Investments | 88.23M | 30.82M |
Long-Term Investments | 61.1M | n/a |
Other Long-Term Assets | 3.23M | 3M |
Receivables | 1.67M | 253K |
Inventory | n/a | n/a |
Other Current Assets | n/a | 2.73M |
Total Current Assets | 357.77M | 129.99M |
Property-Plant & Equipment | 3.35M | 2.68M |
Goodwill & Intangibles | n/a | n/a |
Total Long-Term Assets | 67.68M | 5.68M |
Total Assets | 425.45M | 135.66M |
Account Payables | 2.65M | 3.15M |
Deferred Revenue | n/a | n/a |
Short-Term Debt | 816K | n/a |
Other Current Liabilities | 4.17M | 1.84M |
Total Current Liabilities | 10.81M | 11.79M |
Long-Term Debt | 14.8M | 14.81M |
Other Long-Term Liabilities | n/a | 372.22M |
Total Long-Term Liabilities | 16.29M | 388.12M |
Total Liabilities | 27.1M | 399.91M |
Total Debt | 17.11M | 16.41M |
Book Value | 398.35M | -264.25M |
Book Value Per Share | 8.99 | -6.32 |
Common Stock | 67K | 24K |
Retained Earnings | -321.17M | -292.23M |
Comprehensive Income | -95K | 12K |
Shareholders Equity | 398.35M | -264.25M |
Total Investments | 149.33M | 30.82M |
Add to Watchlist
Select watchlists to add or remove AVLN